10528974.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 24	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:03:29 ON 18 OCT 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:03:39 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10528974.str





chain nodes :
6 7 8 9 10
ring nodes :
1 2 3 4 5
chain bonds :
4-6 5-7 7-8 7-10 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
5-7 7-8 7-10
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-6 8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 10:03:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 120 TO ITERATE

100.0% PROCESSED 120 ITERATIONS 0 ANSWERS

10528974.trn

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1743 TO 3057
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 10:04:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2415 TO ITERATE

100.0% PROCESSED 2415 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10528974a.str

chain nodes :
6 7 8 9
ring nodes :
1 2 3 4 5
chain bonds :
4-6 5-7 7-8 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
5-7 7-8
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-6 8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 10:04:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      120 TO ITERATE

100.0% PROCESSED      120 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1743 TO     3057
PROJECTED ANSWERS:               0 TO        0

L5             0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 10:05:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2415 TO ITERATE

100.0% PROCESSED     2415 ITERATIONS                               0 ANSWERS
SEARCH TIME: 00.00.01

L6             0 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10528974b.str
```





```
chain nodes :
6  7  8
ring nodes :
1  2  3  4  5
chain bonds :
5-6  6-7  7-8
ring bonds :
1-2  1-5  2-3  3-4  4-5
exact/norm bonds :
5-6  6-7
exact bonds :
1-2  1-5  2-3  3-4  4-5  7-8
```

10528974.trn

isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS

L7 STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 10:06:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 150 TO ITERATE

100.0% PROCESSED 150 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2266 TO 3734
PROJECTED ANSWERS: 9 TO 360

L8 9 SEA SSS SAM L7

=> s l7 sss full
FULL SEARCH INITIATED 10:06:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2898 TO ITERATE

100.0% PROCESSED 2898 ITERATIONS 157 ANSWERS
SEARCH TIME: 00.00.01

L9 157 SEA SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10528974c.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5
chain bonds :
4-10 5-6 6-7 7-8 10-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
5-6 6-7 10-11
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-10 7-8

isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:CLASS
11:CLASS

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10
SAMPLE SEARCH INITIATED 10:08:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 120 TO ITERATE

100.0% PROCESSED 120 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1743 TO 3057
PROJECTED ANSWERS: 6 TO 266

L11 6 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 10:08:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2415 TO ITERATE

100.0% PROCESSED 2415 ITERATIONS 101 ANSWERS
SEARCH TIME: 00.00.01

L12 101 SEA SSS FUL L10

=>
Uploading C:\Program Files\Stnexp\Queries\10528974d.str





chain nodes :
6 7 8 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
4-10 5-6 6-7 7-8 10-11 10-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
5-6 6-7 10-11
exact bonds :
1-2 1-5 2-3 3-4 4-5 4-10 7-8 10-12
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:CLASS
11:CLASS 12:CLASS

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 10:09:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 120 TO ITERATE

```
100.0% PROCESSED      120 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1743 TO     3057
PROJECTED ANSWERS:               0 TO        0

L14             0 SEA SSS SAM L13

=> s l13 sss full
FULL SEARCH INITIATED 10:09:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2415 TO ITERATE

100.0% PROCESSED     2415 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L15             0 SEA SSS FUL L13

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   862.75     862.96

FILE 'HCAPLUS' ENTERED AT 10:09:30 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Oct 2007  VOL 147 ISS 17
FILE LAST UPDATED: 17 Oct 2007  (20071017/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 10:03:29 ON 18 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 10:03:39 ON 18 OCT 2007
L1               STRUCTURE UPLOADED
L2             0 S L1
L3             0 S L1 SSS FULL
L4               STRUCTURE UPLOADED
L5             0 S L4
L6             0 S L4 SSS FULL
```

```
L7                STRUCTURE UPLOADED
L8              9 S L7
L9            157 S L7 SSS FULL
L10               STRUCTURE UPLOADED
L11             6 S L10
L12           101 S L10 SSS FULL
L13               STRUCTURE UPLOADED
L14             0 S L13
L15             0 S L13 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 10:09:30 ON 18 OCT 2007

=> s l9
L16         173 L9

=> s l12
L17          22 L12

=> s l16 and cyclisation
            543 CYCLISATION
             85 CYCLISATIONS
            606 CYCLISATION
                  (CYCLISATION OR CYCLISATIONS)
L18           0 L16 AND CYCLISATION

=> s l17 and cyclisation
            543 CYCLISATION
             85 CYCLISATIONS
            606 CYCLISATION
                  (CYCLISATION OR CYCLISATIONS)
L19           0 L17 AND CYCLISATION

=> s l17 and py<=2002
      22908126 PY<=2002
L20          17 L17 AND PY<=2002

=> s l20 and thienopyrrole
            159 THIENOPYRROLE
             69 THIENOPYRROLES
            176 THIENOPYRROLE
                  (THIENOPYRROLE OR THIENOPYRROLES)
L21           2 L20 AND THIENOPYRROLE

=> s l16 and thienopyrrole
            159 THIENOPYRROLE
             69 THIENOPYRROLES
            176 THIENOPYRROLE
                  (THIENOPYRROLE OR THIENOPYRROLES)
L22           2 L16 AND THIENOPYRROLE

=> d l21 ibib abs hitstr tot

L21  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1976:59258  HCAPLUS
DOCUMENT NUMBER:          84:59258
TITLE:                    Reactivity of 2-aminothiophenes.  Application to
                          synthesis of thieno[2,3-b]pyrroles
AUTHOR(S):                Wierzbicki, Michel; Cagniant, Denise; Cagniant, Paul
CORPORATE SOURCE:         Fac. Sci., Univ. Metz, Metz, Fr.
SOURCE:                   Bulletin de la Societe Chimique de France (
```

1975), (7-8, Pt. 2), 1786-92
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 84:59258
GI For diagram(s), see printed CA Issue.
AB Thienopyrroles I (R = H, Ac; R1 = OH, NH2; R2 = CH2CO2Et, Me; R3 = CO2Et, Ac) were prepared by treating the thiophenes II (R4 = H; R5 = CO2Et, CN) with BrCH2CO2Et and Dieckmann reaction of II (R4 = CH2CO2Et). I (R1 = OH) were alkylated with BrCH2CO2Et or acetylated. I (R2 = NH2) were acetylated and diazotized.
IT 58168-32-4P 58168-33-5P 58168-40-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58168-32-4 HCAPLUS
CN 3-Thiophenecarboxylic acid, 5-acetyl-2-[(carboxymethyl)amino]-4-methyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 58168-33-5 HCAPLUS
CN 2,4-Thiophenedicarboxylic acid, 5-[(carboxymethyl)amino]-3-methyl-, 2,4-diethyl ester (9CI) (CA INDEX NAME)



RN 58168-40-4 HCAPLUS
CN 2,4-Thiophenedicarboxylic acid, 5-[(carboxymethyl)amino]-3-methyl- (9CI) (CA INDEX NAME)



L21 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1974:552041 HCAPLUS
DOCUMENT NUMBER: 81:152041

TITLE: Synthesis of substituted thieno[2,3-b]pyrroles
AUTHOR(S): Crochet, Roy A., Jr.; Boatright, Joan T.; Blanton, C. DeWitt, Jr.; Wie, Chwang T.; Hocholzer, W. E.
CORPORATE SOURCE: Sch. Pharm., Athens, GA, USA
SOURCE: Journal of Heterocyclic Chemistry (1974), 11(2), 143-50
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 81:152041
GI For diagram(s), see printed CA Issue.
AB Substituted thieno[2,3-b]pyrroles were prepared from readily available starting materials. Thus, 2-amino-3cyano-4,5-dimethylthiophene was treated with HCOCO2Me followed by reduction and acetylation to give the thiophene I, which was cyclized to give the thienopyrrole II.
IT 53976-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 53976-22-0 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-[(carboxymethyl)amino]-5-methyl-4-phenyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



IT 53976-21-9P 53976-25-3P 54010-93-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53976-21-9 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-[(carboxymethyl)amino]-4-phenyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 53976-25-3 HCAPLUS
CN Glycine, N-[3-(aminocarbonyl)-4,5-dimethyl-2-thienyl]- (9CI) (CA INDEX NAME)



RN 54010-93-4 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-[(carboxymethyl)amino]-4,5-dimethyl-, 3-ethyl ester (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.74	904.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'REGISTRY' ENTERED AT 10:16:25 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7
DICTIONARY FILE UPDATES: 17 OCT 2007 HIGHEST RN 950885-37-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

10528974.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10528974f.str

chain nodes :
9 10
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
4-9 7-10
ring bonds :
1-2 1-5 2-3 3-6 4-5 4-8 5-6 6-7 7-8
exact/norm bonds :
1-2 1-5 2-3 3-6 4-5 4-8 5-6 6-7 7-8
exact bonds :
4-9 7-10
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS

L23 STRUCTURE UPLOADED

=> d l23
L23 HAS NO ANSWERS
L23 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l23
SAMPLE SEARCH INITIATED 10:16:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS

```
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:             5 TO      234
PROJECTED ANSWERS:                0 TO        0

L24           0 SEA SSS SAM L23

=> s l23 sss full
FULL SEARCH INITIATED 10:16:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      100 TO ITERATE

100.0% PROCESSED      100 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L25           0 SEA SSS FUL L23

=>
Uploading C:\Program Files\Stnexp\Queries\10528974g.str
```





```
chain nodes :
9  11
ring nodes :
1  2  3  4  5  6  7  8
chain bonds :
4-9  8-11
ring bonds :
1-2  1-5  2-3  3-6  4-5  4-8  5-6  6-7  7-8
exact/norm bonds :
1-2  1-5  2-3  3-6  4-5  4-8  5-6  6-7  7-8
exact bonds :
4-9  8-11
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:CLASS  11:CLASS



L26     STRUCTURE UPLOADED

=> d l26
L26 HAS NO ANSWERS
L26             STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l26
SAMPLE SEARCH INITIATED 10:19:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       27 TO ITERATE

100.0% PROCESSED       27 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          229 TO      851
PROJECTED ANSWERS:               1 TO       80

L27           1 SEA SSS SAM L26

=> s l26 sss full
FULL SEARCH INITIATED 10:19:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      422 TO ITERATE

100.0% PROCESSED      422 ITERATIONS                               11 ANSWERS
SEARCH TIME: 00.00.01

L28           11 SEA SSS FUL L26

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   345.55    1250.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.56

FILE 'HCAPLUS' ENTERED AT 10:19:38 ON 18 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 18 Oct 2007 VOL 147 ISS 17
FILE LAST UPDATED: 17 Oct 2007 (20071017/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:03:29 ON 18 OCT 2007)

FILE 'REGISTRY' ENTERED AT 10:03:39 ON 18 OCT 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 9 S L7
L9 157 S L7 SSS FULL
L10 STRUCTURE UPLOADED
L11 6 S L10
L12 101 S L10 SSS FULL
L13 STRUCTURE UPLOADED
L14 0 S L13
L15 0 S L13 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:09:30 ON 18 OCT 2007
L16 173 S L9
L17 22 S L12
L18 0 S L16 AND CYCLISATION
L19 0 S L17 AND CYCLISATION
L20 17 S L17 AND PY<=2002
L21 2 S L20 AND THIENOPYRROLE
L22 2 S L16 AND THIENOPYRROLE

FILE 'REGISTRY' ENTERED AT 10:16:25 ON 18 OCT 2007
L23 STRUCTURE UPLOADED
L24 0 S L23
L25 0 S L23 SSS FULL
L26 STRUCTURE UPLOADED
L27 1 S L26
L28 11 S L26 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:19:38 ON 18 OCT 2007

=> s l28
L29 31 L28

=> s l29 and l16
L30 0 L29 AND L16

=> s l29 and l17
L31 0 L29 AND L17

```
=> s l29 and py<=2002
     22908126 PY<=2002
L32          9 L29 AND PY<=2002

=> s l29 and cyclisation
           543 CYCLISATION
            85 CYCLISATIONS
           606 CYCLISATION
                 (CYCLISATION OR CYCLISATIONS)
L33          0 L29 AND CYCLISATION

=> s l29 and process
       2506214 PROCESS
       1706644 PROCESSES
       3736944 PROCESS
                 (PROCESS OR PROCESSES)
L34          2 L29 AND PROCESS

=> s thienopyrrole
           159 THIENOPYRROLE
            69 THIENOPYRROLES
L35        176 THIENOPYRROLE
                 (THIENOPYRROLE OR THIENOPYRROLES)

=> s l35 and process
       2506214 PROCESS
       1706644 PROCESSES
       3736944 PROCESS
                 (PROCESS OR PROCESSES)
L36          8 L35 AND PROCESS

=> s l36 and cyclisation
           543 CYCLISATION
            85 CYCLISATIONS
           606 CYCLISATION
                 (CYCLISATION OR CYCLISATIONS)
L37          0 L36 AND CYCLISATION

=> d his

     (FILE 'HOME' ENTERED AT 10:03:29 ON 18 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 10:03:39 ON 18 OCT 2007
L1               STRUCTURE UPLOADED
L2             0 S L1
L3             0 S L1 SSS FULL
L4               STRUCTURE UPLOADED
L5             0 S L4
L6             0 S L4 SSS FULL
L7               STRUCTURE UPLOADED
L8             9 S L7
L9           157 S L7 SSS FULL
L10              STRUCTURE UPLOADED
L11            6 S L10
L12          101 S L10 SSS FULL
L13              STRUCTURE UPLOADED
L14            0 S L13
L15            0 S L13 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 10:09:30 ON 18 OCT 2007
```

```
L16          173 S L9
L17           22 S L12
L18            0 S L16 AND CYCLISATION
L19            0 S L17 AND CYCLISATION
L20           17 S L17 AND PY<=2002
L21            2 S L20 AND THIENOPYRROLE
L22            2 S L16 AND THIENOPYRROLE

     FILE 'REGISTRY' ENTERED AT 10:16:25 ON 18 OCT 2007
L23              STRUCTURE UPLOADED
L24            0 S L23
L25            0 S L23 SSS FULL
L26              STRUCTURE UPLOADED
L27            1 S L26
L28           11 S L26 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 10:19:38 ON 18 OCT 2007
L29           31 S L28
L30            0 S L29 AND L16
L31            0 S L29 AND L17
L32            9 S L29 AND PY<=2002
L33            0 S L29 AND CYCLISATION
L34            2 S L29 AND PROCESS
L35          176 S THIENOPYRROLE
L36            8 S L35 AND PROCESS
L37            0 S L36 AND CYCLISATION

=> d l32 ibib abs hitstr tot

L32  ANSWER 1 OF 9  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:157498  HCAPLUS
DOCUMENT NUMBER:          140:199313
TITLE:                    Preparation of fused pyrrolylcarboxamides as glycogen
                          phosphorylase inhibitors
INVENTOR(S):              Daisy, Joe
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   Eur. Pat. Appl., 71 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   ----------  --------------------    --------
     EP 1391460            A1    20040225    EP 2003-20676           20000918
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY
     EP 1088824            A2    20010404    EP 2000-308131          20000918 <--
     EP 1088824            A3    20010627
     EP 1088824            B1    20040107
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     US 2002183369         A1    20021205    US 2002-117370          20020405 <--
     US 6576653            B2    20030610
     US 2003195361         A1    20031016    US 2003-367002          20030214
     US 6828343            B2    20041207
PRIORITY APPLN. INFO.:                       US 1999-157148P     P   19990930
                                             EP 2000-308131      A3  20000918
                                             US 2000-670759      A3  20000927
```

US 2002-117370 A3 20020405

OTHER SOURCE(S): MARPAT 140:199313

GI



I

AB Title compds. [I; Q = substituted aryl, heteroaryl; Z, X = C, CH, CH2, N, O, S; X1 = NRa, CH2, O , S; dotted lines = bond, null; both dotted lines are not simultaneously bonds; R1 = H, halo, alkoxy, alkylthio, alkyl, CF3, NH2, alkylamino, dialkylamino, NO2, CN, CO2H, carboxyalkyl, alkenyl, alkynyl; Ra, Rb = H, alkyl; Y = CH(OH), null; R2R3 = atoms to form a 5-6 membered ring containing 0-3 heteroatoms and 0-2 double bonds; R4 = COA; A = NRdRd, NRaCH2CH2ORa, N-heterocyclyl; Rd = H, alkyl, alkoxy, aryl, (substituted) aryl, heteroaryl; Rc = H, CO2Ra, ORa, SRa, NRaRa; n = 1-3], were prepared for treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia (no data). Thus, 6H-thieno[2,3-b]pyrrole-5-carboxylic acid and (3S)-amino-1-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-4-phenylbutan-1-one were coupled using 4-(dimethylamino)pyridine, 1-hydroxybenzotriazole hydrate and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH2Cl2/DMF to give 6H-thieno[2,3-b]pyrrole-5-carboxylic acid [(1S)-benzyl-3-((3R,4S)-dihydroxypyrrolidin-1-yl)-(2R)-hydroxy-3-oxopropyl]amide.

IT 51856-25-8, 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid
58963-45-4, 2-Formyl-6H-thieno[2,3-b]pyrrole-5-carboxylic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused pyrrolylcarboxamides as glycogen phosphorylase inhibitors)

RN 51856-25-8 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



RN 58963-45-4 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-formyl- (9CI) (CA INDEX NAME)



IT 332098-83-6P, 2-Bromo-6H-thieno[2,3-b]pyrrole-5-carboxylic acid

332098-87-0P, 2-Methyl-6H-thieno[2,3-b]pyrrole-5-carboxylic acid
332099-03-3P, 2-Chloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid
332099-07-7P, 2,4-Dichloro-6H-thieno[2,3-b]pyrrole-5-carboxylic acid 332099-16-8P, 2-Cyano-6H-thieno[2,3-b]pyrrole-5-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused pyrrolylcarboxamides as glycogen phosphorylase inhibitors)

RN 332098-83-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-bromo- (9CI) (CA INDEX NAME)



RN 332098-87-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 332099-03-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



RN 332099-07-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2,4-dichloro- (9CI) (CA INDEX NAME)



RN 332099-16-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-cyano- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:185126 HCAPLUS
DOCUMENT NUMBER: 136:247485
TITLE: Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
INVENTOR(S): Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020530	A1	20020314	WO 2001-SE1880	20010831 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2417594	A1	20020314	CA 2001-2417594	20010831 <--
AU 200182833	A	20020322	AU 2001-82833	20010831 <--
EP 1317459	A1	20030611	EP 2001-961577	20010831
EP 1317459	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013606	A	20030624	BR 2001-13606	20010831
CN 1473163	A	20040204	CN 2001-818322	20010831
JP 2004508376	T	20040318	JP 2002-525151	20010831
AT 263772	T	20040415	AT 2001-961577	20010831
HU 2004000784	A2	20040728	HU 2004-784	20010831
HU 2004000784	A3	20070928		
NZ 524011	A	20040827	NZ 2001-524011	20010831
PT 1317459	T	20040831	PT 2001-961577	20010831
ES 2217183	T3	20041101	ES 2001-1961577	20010831
EE 200300083	A	20041215	EE 2003-83	20010831
CN 1896078	A	20070117	CN 2006-10081896	20010831
ZA 2003001013	A	20040505	ZA 2003-1013	20030205
IN 2003MN00191	A	20050211	IN 2003-MN191	20030206
US 2003232875	A1	20031218	US 2003-344506	20030210
MX 2003PA01512	A	20030609	MX 2003-PA1512	20030219
NO 2003001024	A	20030305	NO 2003-1024	20030305
BG 107624	A	20040130	BG 2003-107624	20030310

HK 1055299	A1	20041021	HK 2003-107519		20031016
IN 2006MN00427	A	20070803	IN 2006-MN427		20060413
PRIORITY APPLN. INFO.:			GB 2000-21831	A	20000906
			CN 2001-818322	A3	20010831
			WO 2001-SE1880	W	20010831
			IN 2003-MN191	A3	20030206

OTHER SOURCE(S): MARPAT 136:247485

GI



I



II

AB Title compds. I [R1 = H, halo, NO2, CN , OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4] or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof were prepared possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepared by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxyethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. containing I are described.

IT 332099-03-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)

RN 332099-03-3 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:709687 HCAPLUS
DOCUMENT NUMBER: 135:272869
TITLE: Synthesis of indolyl-amides as glycogen phosphorylase inhibitors for treatment of type 2 diabetes
INVENTOR(S): Treadway, Judith Lee
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 78 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136071	A2	20010926	EP 2001-301979	20010305 <--
EP 1136071	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001302546	A	20011031	JP 2001-78839	20010319 <--
CA 2341344	A1	20010922	CA 2001-2341344	20010320 <--
ZA 2001002318	A	20020920	ZA 2001-2318	20010320 <--
US 2003004162	A1	20030102	US 2001-813335	20010320
HU 2001001158	A2	20020228	HU 2001-1158	20010321 <--
NZ 510677	A	20021025	NZ 2001-510677	20010321 <--

PRIORITY APPLN. INFO.: US 2000-191381P P 20000322
OTHER SOURCE(S): MARPAT 135:272869
GI



I



II

AB Title compds. I [A = CH, C-alkyl, C-halo when the dotted line is a bond; A = CH2, CH-alkyl when the dotted line is not a bond; R1, R10, R11 = H, halo, 4-, 6- or 7-NO2, CN, alkyl, alkoxy, (di/tri)fluoromethyl; R2 = H; R3 = H, alkyl; R4 = H, (hydroxy)alkyl, alkoxy-alkyl, phenyl(hydroxy)alkyl, thienyl-alkyl, etc.; R5 = H, OH, F, alkyl, alkoxy, alkanoyl, amino-alkoxy, etc.; R7 = H, F, alkyl; or R5 and R7 can be taken together to be oxo; R6 = carboxy, alkoxycarbonyl, amido, acyl, alkyl, OH, alkoxy; R9 = H, alkyl, OH, alkoxy, methyleneperfluorinated-alkyl, Ph, pyridyl, thienyl, etc.] and derivs. were prepared Over 50 examples were reported. For instance, 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid was coupled to 2-amino-1-(3,4-dihydroxypyrrolidin-1-yl)-3-phenylpropan-1-one hydrochloride (DCM, DMF, HOBt, EDC, room temperature) to give amide II. Compds. I are glycogen phosphorylase inhibitors used for treating type 2 diabetes mellitus in cases which have not yet presented, but in which there is an increased risk of developing such condition. Combination therapies of I and non-glycogen phosphorylase inhibiting anti-diabetic agents are also claimed.

IT 332099-07-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis of indolyl-amides as glycogen phosphorylase inhibitors for treatment of type 2 diabetes)

RN 332099-07-7 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2,4-dichloro- (9CI) (CA INDEX NAME)



IT 51856-25-8, 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid
58963-45-4 332098-83-6 332098-87-0
332099-03-3 332099-16-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; synthesis of indolyl-amides as glycogen phosphorylase inhibitors for treatment of type 2 diabetes)
RN 51856-25-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



RN 58963-45-4 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-formyl- (9CI) (CA INDEX NAME)



RN 332098-83-6 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-bromo- (9CI) (CA INDEX NAME)



RN 332098-87-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 332099-03-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



RN 332099-16-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-cyano- (9CI) (CA INDEX NAME)



L32 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:246569 HCAPLUS
DOCUMENT NUMBER: 134:266296
TITLE: Preparation of bicyclic pyrrolylcarboxamides as glycogen phosphorylase inhibitors.
INVENTOR(S): Joe, Daisy
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1088824	A2	20010404	EP 2000-308131	20000918 <--
EP 1088824	A3	20010627		
EP 1088824	B1	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 257480	T	20040115	AT 2000-308131	20000918
EP 1391460	A1	20040225	EP 2003-20676	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1088824	T	20040430	PT 2000-308131	20000918
ES 2211454	T3	20040716	ES 2000-308131	20000918
JP 2001131181	A	20010515	JP 2000-285363	20000920 <--
JP 3489819	B2	20040126		
US 6399601	B1	20020604	US 2000-670759	20000927 <--
CA 2321379	A1	20010330	CA 2000-2321379	20000928 <--
MX 2000PA09622	A	20020201	MX 2000-PA9622	20000929 <--
BR 2000004582	A	20010417	BR 2000-4582	20001002 <--
US 2002183369	A1	20021205	US 2002-117370	20020405 <--
US 6576653	B2	20030610		
US 2003195361	A1	20031016	US 2003-367002	20030214
US 6828343	B2	20041207		

PRIORITY APPLN. INFO.:	US 1999-157148P	P	19990930
	EP 2000-308131	A3	20000918
	US 2000-670759	A3	20000927
	US 2002-117370	A3	20020405

OTHER SOURCE(S): MARPAT 134:266296
GI



I

AB Title compds. [I; Q = (substituted) aryl, heteroaryl; X, Z = C, CH, CH2, N, O, S; Y = null, CH(OH); R1 = H, halo, alkoxy, alkylthio, alkyl, CF3, amino, NO2, cyano, CO2H, etc.; R2, R3 = H, halo, alkyl, cyano, alkoxy, alkylthio, CF3, amino, NO2, CO2H, etc.; R2R3 = atoms to form a 5-6 membered ring; R4 = COA; A = amino, specified (substituted) N-heterocyclyl; Rb = H, alkyl], were prepared for treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia (no data). Thus, 6H-thieno[2,3-b]pyrrole-5-carboxylic acid and (3S)-amino-1-[(3R,4S)-dihydroxypyrrolidin-1-yl]-(2R)-hydroxy-4-phenylbutan-1-one (preparation given) were coupled using Et3N/hydroxybenzotriazole/1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to give 6H-thieno[2,3-b]pyrrole-5-carboxylic acid [(1S)-benzyl-3-[(3R,4S)-dihydroxypyrrolidin-1-yl]-(2R)-hydroxy-3-oxopropyl]amide.

IT 51856-25-8 58963-45-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bicyclic pyrrolylcarboxamides as glycogen phosphorylase inhibitors)

RN 51856-25-8 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



RN 58963-45-4 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-formyl- (9CI) (CA INDEX NAME)



IT 332098-83-6P 332098-87-0P 332099-03-3P
332099-07-7P 332099-16-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic pyrrolylcarboxamides as glycogen phosphorylase inhibitors)

RN 332098-83-6 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-bromo- (9CI) (CA INDEX NAME)



RN 332098-87-0 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 332099-03-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



RN 332099-07-7 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2,4-dichloro- (9CI) (CA INDEX NAME)



RN 332099-16-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-cyano- (9CI) (CA INDEX NAME)



L32 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:639793 HCAPLUS
DOCUMENT NUMBER: 132:12271
TITLE: Improved syntheses of [3,2-b]- and [2,3-b]-fused selenolo- and thienopyrroles, and of furo[3,2-b]pyrrole
AUTHOR(S): Welch, Michael; Phillips, Robert S.
CORPORATE SOURCE: Department of Chemistry, Department of Biochemistry

and Molecular Biology, and Center for Metalloenzyme Studies, University of Georgia, Athens, GA, 30602-2556, USA
SOURCE: Heterocyclic Communications (1999), 5(4), 305-310
CODEN: HCOMEX; ISSN: 0793-0283
PUBLISHER: Freund Publishing House Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:12271
AB 5-Carboxyselenolo[3,2-b]pyrrole, 5-carboxyselenolo[2,3-b]pyrrole, 5-carboxythieno[3,2-b]pyrrole, and 5-carboxythieno[2,3-b]pyrrole are smoothly decarboxylated in glycerol at 160-170°, providing greater than 70% yields of the corresponding pyrroles. 5-Carboxyfuro[3,2-b]pyrrole decarboxylates rapidly in refluxing ethanolamine to give greater than 50% yield of furo[3,2-b]pyrrole. By using these decarboxylation conditions, the previously described route to unsubstituted [3,2-b]- and [2,3-b]-fused selenolo- and thienopyrroles, and to furo[3,2-b]pyrrole, has been improved.
IT 51856-25-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of selenolo-, thieno-, and furopyrroles by decarboxylation of selenolo-, thieno-, and furopyrrolecarboxylic acids)
RN 51856-25-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1985:78856 HCAPLUS
DOCUMENT NUMBER: 102:78856
TITLE: Thieno[2,3-b]pyrrole derivatives and their therapeutic use
INVENTOR(S): Wierzbicki, Michel; Bure, Jacques
PATENT ASSIGNEE(S): ADIR, Fr.
SOURCE: Fr. Demande, 17 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2537974	A1	19840622	FR 1982-21090	19821216 <--
FR 2537974	B1	19850315		
US 4608384	A	19860826	US 1983-560419	19831212 <--
DK 8305774	A	19840617	DK 1983-5774	19831215 <--
NO 8304637	A	19840618	NO 1983-4637	19831215 <--
AU 8322458	A	19840621	AU 1983-22458	19831215 <--
EP 114014	A2	19840725	EP 1983-402438	19831215 <--

EP 114014	A3	19840822			
EP 114014	B1	19870520			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
ZA 8309341	A	19840725	ZA 1983-9341		19831215 <--
ES 528088	A1	19841216	ES 1983-528088		19831215 <--
IL 70457	A	19860228	IL 1983-70457		19831215 <--
CA 1212380	A1	19861007	CA 1983-443344		19831215 <--
AT 27277	T	19870615	AT 1983-402438		19831215 <--
JP 59118788	A	19840709	JP 1983-237747		19831216 <--
HU 32831	A2	19840928	HU 1983-4315		19831216 <--
DD 259193	A5	19880817	DD 1983-258084		19831216 <--
PRIORITY APPLN. INFO.:			FR 1982-21090	A	19821216
			EP 1983-402438	A	19831215

OTHER SOURCE(S): CASREACT 102:78856; MARPAT 102:78856
GI



I

AB Acylthienopyrroles I [R = alkyl; R1 = alkyl, Ph, halo-, alkyl-, alkoxy-, nitro-, or (dialkylamino)phenyl; R2 = H, alkyl; R3 = cyano, CO2H, CO2M (M = alkali or alkaline earth metal), carbalkoxy, carbamoyl], which were prepared, are useful as analgesics and antiinflammatory agents (no data). 3-Methyl-4-(4-chlorobenzoyl)thieno[2,3-b]pyrrole was treated with NaOEt and MeCHBrCO2Et, NaOH was added, and the mixture was heated to give I (R = Me, R1 = 4-ClC6H4, R2 = Me, R3 = CO2H).

IT 94103-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and decarboxylation of)

RN 94103-94-3 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-2,5-dicarboxylic acid, 4-(4-chlorobenzoyl)-3-methyl- (9CI) (CA INDEX NAME)



L32 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:558298 HCAPLUS

DOCUMENT NUMBER: 99:158298

TITLE: The [1 + 4] cycloaddition of isocyanides with 1-aryl-2-nitro-1-propenes. Methyl 2-nitro-3-arylpropenoates and methyl 2-nitro-2,4-pentadienoates. Synthesis of 1-hydroxyindoles and 1-hydroxypyrroles

AUTHOR(S): Foucaud, Andre; Razorilalana-Rabearivony, Claudia; Loukakou, Emile; Person, Herve
CORPORATE SOURCE: Groupe Chim. Struct., Univ. Rennes, Rennes, 35042, Fr.
SOURCE: Journal of Organic Chemistry (1983), 48(21), 3639-44
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 99:158298
GI



I

AB The [1 + 4] cycloaddns. of isocyanides with various arylnitrosoalkenes have been investigated. When the aryl groups were (un)substituted Ph, naphthyl, and 2-pyridinyl, the reactions gave the 1-hydroxyindoles, 1-hydroxybenzindoles, and 1-hydroxy-7-azaindole. E.g., cycloaddn. of PhCH:CMeNO2 with Me3CNC gave hydroxyindole I. When the aryl group was thienyl or furyl, fused 1-hydroxypyrroles were obtained. The reaction of isocyanide with Me 2-nitro-2,4-pentadienoates gave 1-hydroxypyrroles. A mechanism involving the formation of an unstable oxazoline N-oxide which decomps. to the reaction products has been suggested.

IT 86969-75-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 86969-75-7 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 4-[[(1,1-dimethylethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:150537 HCAPLUS
DOCUMENT NUMBER: 84:150537
TITLE: Studies in the heterocyclic series. XXV. Synthesis of thieno[2,3-b]pyrrole aldehydes
AUTHOR(S): Soth, Samreth; Farnier, Michel; Fournari, Pierre
CORPORATE SOURCE: Lab. Polarogr. Org., Fac. Sci., Dijon, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1975), (11-12, Pt. 2), 2511-15
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 84:150537

GI



II

AB 2-, 4-, And 5-formylthieno[2,3-b]pyrroles were prepared by Vilsmeier formylation of thieno[2,3-b]pyrrole, prepared by hydrolyzing and decarboxylating Et 6H-thieno[2,3-b]pyrrole-5-carboxylate (I). 2- And 4-formylthieno[2,3-b]pyrroles were also obtained by formylating I, followed by hydrolysis and decarboxylation. 3-Formylthieno[2,3-b]pyrrole was prepared by treating II (R = CHO) with N3CH2CO2Et, cyclizing II (R = CH:CN3CO2Et), hydrolyzing, and decarboxylating.

IT 51856-25-8P 58963-45-4P 58963-49-8P
58982-22-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and decarboxylation of)

RN 51856-25-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



RN 58963-45-4 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-formyl- (9CI) (CA INDEX NAME)



RN 58963-49-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 3-formyl- (9CI) (CA INDEX NAME)



RN 58982-22-2 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 4-formyl- (9CI) (CA INDEX NAME)



L32 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1974:82749 HCAPLUS
DOCUMENT NUMBER: 80:82749
TITLE: Synthesis of 6H-thieno(2,3-b)pyrrole and of formyl derivatives
AUTHOR(S): Farnier, Michel; Soth, Samreth; Fournari, Pierre
CORPORATE SOURCE: Lab. Polarogr. Org., Dijon, Fr.
SOURCE: Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques (1973), 277(21), 1149-51
CODEN: CHDCAQ; ISSN: 0567-6541
DOCUMENT TYPE: Journal
LANGUAGE: French
GI For diagram(s), see printed CA Issue.
AB The thienopyrrole I (R = H) was prepared by hydrolysis of I (R = CO2Et) to give 50% of the acid I (R = CO2H) and decarboxylation in 40% yield. Treatment of the acid with SOCl2-EtOH gave I (R = COSEt) which on reduction gave a small amount of I (R = CHO). Formylation of I (R = H) gave 90% I (R = CHO) together with small amts. of the 2- and 4-carboxaldehydes. The latter 2 compds. were also prepared by formylating I (R = CO2Et), hydrolyzing, and decarboxylating. The thienodipyrrole II was formed by heating thiophene-3,4-dicarboxaldehyde with N3CH2CO2Et.
IT 51856-25-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(Decarboxylation of)
RN 51856-25-8 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid (CA INDEX NAME)



=> d l34 ibib abs hitstr tot

L34 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:795762 HCAPLUS
DOCUMENT NUMBER: 145:211025
TITLE: Thienopyrrole derivatives as glycogen phosphorylase inhibitors and their preparation, pharmaceutical compositions and use for treatment of glycogen phosphorylase mediated diseases
INVENTOR(S): Birch, Alan Martin; Johnstone, Craig; Plowright, Alleyn Thomas; Simpson, Iain; Whittamore, Paul Robert Owen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 93pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082401	A1	20060810	WO 2006-GB349	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006210719	A1	20060810	AU 2006-210719	20060202
CA 2595835	A1	20060810	CA 2006-2595835	20060202
IN 2007DN05663	A	20070817	IN 2007-DN5663	20070723

PRIORITY APPLN. INFO.:
GB 2005-2465 A 20050205
GB 2005-2466 A 20050205
WO 2006-GB349 W 20060202

OTHER SOURCE(S): MARPAT 145:211025
GI



I



II

AB A compound of the formula I or a pharmaceutically-acceptable salt: possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as type 2 diabetes. Processes for the manufacture of compds. and pharmaceutical compns. containing them are described. Compds. of formula I wherein Y is CH or N; R4 and R5 together

are -S-CR6=CR7- or -CR7=CR6S-; R7 and R7 are independently H, halo, NO2, CN, HO, CH2F, CHF2, CF3, CF3O, carboxy, carbamoyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, or C1-4 alkanoyl; n is 0, 1, or 2; each R1 are independently halo, CN, NO2, HO, carboxy, carbamoyl, etc.; Z1 is C1-6 alkylene-CO2H, C3-6 cycloalkylene-CO2, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by hydrolysis of tert-Bu [((1R,2R)-2-{[(2-chloro-6H-thieno[2,3-b]pyrrolo-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl)methoxy]acetate. All the invention compds. were evaluated for their glycogen phosphorylase inhibitory activity (no data).

IT 332099-03-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyrrole derivs. as glycogen phosphorylase inhibitors useful for treatment of glycogen phosphorylase mediated diseases)

RN 332099-03-3 HCAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:719488 HCAPLUS
DOCUMENT NUMBER: 139:246010
TITLE: Preparation of heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
INVENTOR(S): Whittamore, Paul Robert Owen; Bennett, Stuart Norman Lile; Simpson, Iain
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074531	A1	20030912	WO 2003-GB875	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477125	A1	20030912	CA 2003-2477125	20030304
AU 2003209445	A1	20030916	AU 2003-209445	20030304
BR 2003008145	A	20041207	BR 2003-8145	20030304

EP 1483271	A1	20041208	EP 2003-743418		20030304
EP 1483271	B1	20061122			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1639167	A	20050713	CN 2003-805124		20030304
JP 2005524669	T	20050818	JP 2003-572999		20030304
NZ 534684	A	20060224	NZ 2003-534684		20030304
AT 346072	T	20061215	AT 2003-743418		20030304
ES 2276092	T3	20070616	ES 2003-3743418		20030304
ZA 2004006685	A	20051031	ZA 2004-6685		20040823
US 2005131052	A1	20050616	US 2004-506746		20040903
US 7122567	B2	20061017			
MX 2004PA08611	A	20041206	MX 2004-PA8611		20040906
NO 2004004033	A	20041125	NO 2004-4033		20040924
HK 1070365	A1	20070427	HK 2005-103055		20050411
PRIORITY APPLN. INFO.:			GB 2002-5170	A	20020306
			WO 2003-GB875	W	20030304

OTHER SOURCE(S): MARPAT 139:246010

GI



I



II

AB Heterocyclic amides of formula I (most examples are N-indenyl 4H-thieno[3,2-b]pyrrole-5-carboxamides, e.g. 2,3-dichloro-N-[(1R*,2R*)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide (shown as II)) (Z is CH or N; R4 and R5 together are either -SC(R6):C(R7)- or -C(R7):C(R6)S-; R6 and R7 = for example H, halo, C1-4alkyl, and C1-4alkanoyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 = for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 = for example H, hydroxy, aryl, heterocyclyl and C1-4alkyl ((un)substituted by 1 or 2 R8 groups); R4 = for example H, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl; R8 = for example hydroxy, -COCOOR9, -C(O)N(R9)(R10), -NHC(O)R9, (R9)(R10)N- and -COOR9 ; R9 and R10 = for example H, hydroxy, C1-4alkyl ((un)substituted by 1 or 2 R13); R13 = hydroxy, halo, trihalomethyl and C1-4alkoxy) or a pharmaceutically acceptable salt or pro-drug thereof are claimed; they possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity (e.g. type 2 diabetes, insulin resistance, syndrome

X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia, obesity). Processes for the manufacture of said heterocyclic amide derivs. and pharmaceutical compns. containing them are described. Inhibitory activity (IC50) of I in the direction of glycogen synthesis and on glycogen degradation were measure and are generally 100 μM to 1 nM; 4.5 μM for 2,3-dichloro-N-[(1S*,2S*)-1-[(3-thienylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide in the latter assay. Sixty-four example prepns. and/or characterization data for I and 23 for intermediates are included. For example, to prepare 2,3-dichloro-N-[(1R*,2R*)-1-(formylamino)-2,3-dihydro-1H-inden-2-yl]-4H-thieno[3,2-b]pyrrole-5-carboxamide, N-((1R*,2R*)-1-amino-2,3-dihydro-1H-inden-2-yl)-2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamide trifluoroacetate (0.5 mmol), formic acid (1.4 mmol), DIPEA (1.0 mmol) and HOBT (0.5 mmol) were dissolved in CH2Cl2 (5 mL), stirred for 5 min, EDCI (0.625 mmol) added and the reaction stirred for 1 h; formic acid (1.4 mmol) and EDCI (1.25 mmol) were added, the reaction stirred for 2 h and the volatiles removed by evaporation under reduced pressure; workup gave 89% of the product as a white foam. The carboxamide reactant was prepared (82 %) by deprotection of 2,3-dichloro-5-[N-[(1R*,2R*)-1-[[N-(1,1-dimethylethoxy)carbonyl]amino]indan-2-yl]carbamoyl]-4H-thieno[3,2-b]pyrrole using trifluoroacetic acid and this reactant was prepared (80 %) from 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole (preparation given) and trans-2-amino-1-[[(1,1-dimethylethoxy)carbonyl]amino]indan (preparation given) using DIPEA, HOBT in CH2Cl2 followed by EDCI.

IT 332099-03-3P, 5-Carboxy-2-chloro-6H-thieno[2,3-b]pyrrole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic amide derivs. having glycogen phosphorylase inhibitory activity)

RN 332099-03-3 HCAPLUS

CN 6H-Thieno[2,3-b]pyrrole-5-carboxylic acid, 2-chloro- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l36 ibib abs hitstr tot

L36 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:626898 HCAPLUS

DOCUMENT NUMBER: 147:235041

TITLE: A General Modular Method of Azaindole and Thienopyrrole Synthesis via Pd-Catalyzed Tandem Couplings of gem-Dichloroolefins

AUTHOR(S): Fang, Yuan-Qing; Yuen, Josephine; Lautens, Mark

CORPORATE SOURCE: Davenport Chemistry Laboratories, Department of Chemistry, Toronto, ON, M5S 3H6, Can.

SOURCE: Journal of Organic Chemistry (2007), 72(14), 5152-5160
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB A palladium-catalyzed reaction of gem-dichloroolefins and a boronic acid via a tandem intramol. C-N and intermol. Suzuki coupling process gave corresponding substituted azaindoles or thienopyrroles. This method is a very modular protocol to synthesize all four isomers of azaindole and two isomers of thienopyrroles in good to excellent yield. E.g., cyclization of gem-dichloroolefin I with PhB(OH)2 in presence of Pd(OAc)2/S-Phos gave 79% azaindole II.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:795762 HCAPLUS

DOCUMENT NUMBER: 145:211025

TITLE: Thienopyrrole derivatives as glycogen phosphorylase inhibitors and their preparation, pharmaceutical compositions and use for treatment of glycogen phosphorylase mediated diseases

INVENTOR(S): Birch, Alan Martin; Johnstone, Craig; Plowright, Alleyn Thomas; Simpson, Iain; Whittamore, Paul Robert Owen

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 93pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082401	A1	20060810	WO 2006-GB349	20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006210719	A1	20060810	AU 2006-210719	20060202
CA 2595835	A1	20060810	CA 2006-2595835	20060202
IN 2007DN05663	A	20070817	IN 2007-DN5663	20070723

PRIORITY APPLN. INFO.: GB 2005-2465 A 20050205
GB 2005-2466 A 20050205
WO 2006-GB349 W 20060202

OTHER SOURCE(S): MARPAT 145:211025
GI



I



II

AB A compound of the formula I or a pharmaceutically-acceptable salt: possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as type 2 diabetes. Processes for the manufacture of compds. and pharmaceutical compns. containing them are described. Compds. of formula I wherein Y is CH or N; R4 and R5 together are -S-CR6=CR7- or -CR7=CR6S-; R7 and R7 are independently H, halo, NO2, CN, HO, CH2F, CHF2, CF3, CF3O, carboxy, carbamoyl, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 alkoxy, or C1-4 alkanoyl; n is 0, 1, or 2; each R1 are independently halo, CN, NO2, HO, carboxy, carbamoyl, etc.; Z1 is C1-6 alkylene-CO2H, C3-6 cycloalkylene-CO2, etc.; and their pharmaceutically acceptable salts are claimed. Example compound II was prepared by hydrolysis of tert-Bu [((1R,2R)-2-{[(2-chloro-6H-thieno[2,3-b]pyrrolo-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl)methoxy]acetate. All the invention compds. were evaluated for their glycogen phosphorylase inhibitory activity (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:792922 HCAPLUS
DOCUMENT NUMBER: 145:239247
TITLE: Electrically conductive conjugated polymer fiber, preparation and use thereof
INVENTOR(S): Mather, Patrick T.; Sotzing, Gregory A.
PATENT ASSIGNEE(S): University of Connecticut, USA
SOURCE: PCT Int. Appl., 73pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084088	A1	20060810	WO 2006-US3764	20060131

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2007089845	A1	20070426	US 2006-343552	20060131
PRIORITY APPLN. INFO.:			US 2005-648588P	P 20050131

AB Described are conjugated polymer fibers prepared by the method comprising electrospinning a solution of intrinsically conductive polymer, intrinsically conductive polymer precursor, or a combination thereof to form a fiber; and crosslinking the intrinsically conductive polymer, intrinsically conductive polymer precursor, or a combination thereof. The conjugated polymer fibers, which can be nanofibers, may be formed into structures in the form of a nonwoven mat or a mat comprising aligned conjugated polymer fibers, or formed into an article such as an electrochromic window or display device. A method of preparing a micropattern of conjugated polymer fiber is further disclosed.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:308442 HCAPLUS
DOCUMENT NUMBER: 140:339191
TITLE: Process for the preparation of thieno[2,3-b]pyrrole derivatives
INVENTOR(S): Murray, Paul Michael; Parker, Jeremy Stephen; Schofield, Paul; Stocker, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031194	A1	20040415	WO 2003-GB4217	20030929

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2500145	A1	20040415	CA 2003-2500145		20030929
AU 2003269219	A1	20040423	AU 2003-269219		20030929
EP 1549654	A1	20050706	EP 2003-750995		20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003014966	A	20050802	BR 2003-14966		20030929
CN 1688587	A	20051026	CN 2003-823617		20030929
JP 2006505541	T	20060216	JP 2004-540943		20030929
NO 2005001393	A	20050420	NO 2005-1393		20050316
ZA 2005002340	A	20050919	ZA 2005-2340		20050318
US 2006035953	A1	20060216	US 2005-528974		20050323
MX 2005PA03327	A	20050705	MX 2005-PA3327		20050329
PRIORITY APPLN. INFO.:			GB 2002-22912	A	20021003
			WO 2003-GB4217	W	20030929

OTHER SOURCE(S): MARPAT 140:339191
GI



I



II



III

AB A safer process for preparing a compound of formula I (R4, R5 = independently H, halo, nitro, fluoromethyl, etc.; R6 = H or a protecting group), which comprises cyclization of a compound of formula II (R7 = a nitrogen protecting group) and removing the group R7 or any protecting group R6, is disclosed. For example, Curtius rearrangement of 5-chlorothiophene-2-carboxylic acid using diphenylphosphoryl azide in the presence of tert-butanol, followed by acid hydrolysis (83%), gave N-(5-chloro-2-thienyl)acetamide. Vilsmeier-Haack formylation of the acetamide (87%) and substitution with Me bromoacetate (59%), afforded Me N-acetyl-N-(5-chloro-3-formyl-2-thienyl)glycinate, II (R4 = H, R5 = Cl, R6 = Me, R7 = COMe). Cyclization of II provided Me 2-chloro-6H-thieno[2,3-b]pyrrole-5-carboxylate in 93%, I (R4 = H, R5 = Cl, R6 = Me). The use of these novel intermediates in the formation of pharmaceutical compds. III (R4, R5 = as defined above; R14 = H, alkyl; R15 = H, halo, cyano, mercapto, etc.; R16 = H, alkyl, R17 = H, halo, amino, hydroxy, carbamoyl, etc.) is also claimed.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:308441 HCAPLUS
DOCUMENT NUMBER: 140:339190
TITLE: Process for the preparation of thieno[3,2-b]pyrrole derivatives

INVENTOR(S): Butters, Michael; Schofield, Paul; Stocker, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031193	A1	20040415	WO 2003-GB4211	20030929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498843	A1	20040415	CA 2003-2498843	20030929
AU 2003267656	A1	20040423	AU 2003-267656	20030929
EP 1549653	A1	20050706	EP 2003-748348	20030929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014312	A	20050726	BR 2003-14312	20030929
CN 1688588	A	20051026	CN 2003-823736	20030929
JP 2006503077	T	20060126	JP 2004-540938	20030929
NO 2005001047	A	20050428	NO 2005-1047	20050225
US 2005272938	A1	20051208	US 2005-528612	20050321
MX 2005PA03387	A	20050622	MX 2005-PA3387	20050330
ZA 2005001742	A	20060329	ZA 2005-1742	20060119
PRIORITY APPLN. INFO.:			GB 2002-22909 A	20021003
			WO 2003-GB4211 W	20030929

OTHER SOURCE(S): MARPAT 140:339190
GI





AB A safer process for preparing a compound of formula I (R4, R5 = independently H, halo, nitro, fluoromethyl, etc.; R6 = H or a protecting group), which comprises cyclization of a compound of formula II (R7 = a nitrogen protecting group) and removing the group R7 or any protecting group R6,. is disclosed. For example, chlorination of thiophene-3-carboxaldehyde (78%) and oxidation, gave 4,5-dichlorothiophene-3-carboxylic acid. Curtius rearrangement of the acid using diphenylphosphorylazide in the presence of tert-butanol (78%), followed by formylation (63%), afforded tert-Bu (4,5-dichloro-2-formyl-3-thienyl)carbamate. Substitution of the carbamate with Me bromoacetate and hydrolysis by acetic acid, provided Me N-acetyl-N-(4,5-dichloro-2-formyl-3-thienyl)glycinate, II (R4 = R5 = Cl, R6 = Me, R7 = COMe). Cyclization of II (45%), followed by hydrolysis (100%), gave the final compound 2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxylic acid, I (R4 = R5 = Cl, R6 = Me). The use of these novel intermediates in the formation of pharmaceutical compds. III (R4, R5 = as defined above; R14 =H, alkyl; R15 = H, halo, cyano, mercapto, etc.; R16 = H, alkyl; R17 = H, halo, amino, hydroxy, carbamoyl, etc.) is also claimed.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:182887 HCAPLUS
DOCUMENT NUMBER: 140:235694
TITLE: Preparation of thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
INVENTOR(S): Arnould, Jean Claude
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018479	A1	20040304	WO 2003-GB3603	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003267551	A1	20040311	AU 2003-267551	20030818
EP 1532154	A1	20050525	EP 2003-748242	20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508050	T	20060309	JP 2004-530353	20030818
US 2006004053	A1	20060105	US 2005-525109	20050218
PRIORITY APPLN. INFO.:			EP 2002-292076 A	20020821
			WO 2003-GB3603 W	20030818

OTHER SOURCE(S): MARPAT 140:235694
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = bond or (un)substituted alkylene; R1 = H, (un)substituted alkyl, cycloalkyl, or cycloalkylalkyl; R2 = (un)substituted mono- or bicyclic aromatic ring structure; R4 = H; R5 = (un)substituted heterocyclic ring containing 1-4 heteroatoms selected from O, N and S, hydroxyalkyl, alkylcarbonyl, etc.; R3 and R3a = independently H, (un)substituted alkyl or together represent a carbonyl; R7 = H or (un)substituted alkyl; R8 and X = when X represents CH, R8 represents NO2, when X represents N, R8 is selected from CN, OH, H, alkoxy, etc., or the combination XR8 equals CO] are prepared and disclosed as compds. useful as gonadotropin releasing hormone antagonists. Thus, e.g., II was prepared via condensation of 2-[2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-5-(3,5-dimethylphenyl)-6H-thieno[2,3-b]pyrrol-4-yl]ethylamine (preparation given) with diphenyl-N-cyanocarbonimidate and subsequent substitution with 3-(pyridin-4-yl)pyrrolidine. I have activity at a concentration from 1nM to 5μM. The invention also relates to pharmaceutical formulations of said compds., methods of treatment using said compds. and to processes for the preparation of said compds.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:41479 HCAPLUS
DOCUMENT NUMBER: 140:111812
TITLE: Preparation of thienopyrrole derivatives as monomers for electroconductive polymers
INVENTOR(S): Kato, Masahiko; Kaneko, Akira
PATENT ASSIGNEE(S): Nippon Soda Co.,ltd., Japan
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005297	A1	20040115	WO 2003-JP8266	20030630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004035507	A	20040205	JP 2002-197401	20020705
AU 2003246132	A1	20040123	AU 2003-246132	20030630
EP 1557419	A1	20050727	EP 2003-738573	20030630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005222241	A1	20051006	US 2004-520050	20041230

PRIORITY APPLN. INFO.: JP 2002-197401 A 20020705
WO 2003-JP8266 W 20030630

OTHER SOURCE(S): MARPAT 140:111812

GI



I

AB The title derivs. I [R1 and R2 each independently represents hydrogen or an optionally substituted C1-10 hydrocarbon group] are prepared A process for preparing I (e.g., 3,5-dihydro-1H-thieno[3,4-c]pyrrole) is disclosed.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:765232 HCAPLUS
DOCUMENT NUMBER: 138:39203
TITLE: Synthesis of Photochromic 1,2-Diheteroarylethene Using Regioselective Acylation of Thienopyrroles
AUTHOR(S): Krayushkin, Michael M.; Yarovenko, Vladimir N.; Semenov, Stanislav L.; Zavarzin, Igor V.; Ignatenko, Anatoliy V.; Martynkin, Andrey Yu.; Uzhinov, Boris M.
CORPORATE SOURCE: N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, 119991, Russia
SOURCE: Organic Letters (2002), 4(22), 3879-3881
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:39203

GI



I



II

AB The influence of catalysts, acid chlorides, and solvents in the acylation of Me 2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate (I) was studied.

Conditions for the regioselective acylation processes were found. Thienopyrrole-based photochromic compound II was synthesized for the first time.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	114.41	1364.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.82	-16.38

STN INTERNATIONAL LOGOFF AT 10:27:10 ON 18 OCT 2007